Renal Calculi
[Renal Calculi]
EPTIS factsheet 1177240 | Last revision 2025-01-14 | URL: https://www.eptis.bam.de/pts1177240 https://www.eptis.bam.de/pts1177240
| PT provider | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PT provider | Weqas Weqas | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Based in | United Kingdom | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Language(s) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Remarks | Renal stones (calculi), and renal stone disease (nephrolithiasis or urolithiasis), are a common problem worldwide with a prevalence of approximately 10% in men and 7% in women and an estimated 5-year recurrence rate of up to 50%. Renal stones are associated with systemic diseases like Type 2 diabetes mellitus, obesity, dyslipidaemia, and hypertension. The programme provides an independent assessment of the performance of calculi analyses in the laboratory. The aim is to ensure that participating laboratories clearly identify the chemical composition of calculi to avoid implementation of ineffective and, in some cases, life-changing treatments. In addition, by the inclusion of occasional rare sample types, the programme assesses whether laboratories recognise and act appropriately when faced with unusual samples. The chemical composition of the matrix and any admixtures are used as the target value. Although the ratio of composition is displayed and the results from the participants recorded, the percentage composition is not scored. The aim of the programme is to assess the ability of participants to correctly identify the compounds in the matrix. Participants get 1 point for each sample component they correctly identify and lose 1 point for each component incorrectly identified. Each sample has a maximum score dependant on the number of compounds present. The well-established performance criteria based on Westgard rules used for other Weqas qualitative programmes are used to assign, good, acceptable, warning and poor comments to the report. Key Features: - Ready to use, stable samples, covering common and rare calculi constituents. - Qualitative and Quantitative analysis. - Suitable for spectroscopy and wet chemistry methods. - Simple scoring based on Westgard rules. For more information: https://www.weqas.com/services/eqa/renal-calculi/ or contact@weqas.com | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Keywords | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Product groups |
Health care / medical devices
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Testing fields |
Medical analysis
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Technical details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Aims of the PT scheme | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Target group of participants | Provides an independent assessment of the performance of calculi analyses in the laboratory. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Linked to specific legislation / standards | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Additional, subsidiary aims | validation of testing methods | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Number of participants | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accredited or otherwise reviewed by a 3rd party |
Accredited by Accreditation by UKAS on the basis of ISO/IEC 17043 on the basis of Accreditation by UKAS on the basis of ISO/IEC 17043 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Operation is commissioned / requested by | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fees and frequency | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Participation fee | https://www.weqas.com/participantzone/subscription-charges/ | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Regularly operated | Yes (Frequency: Bimonthly. Samples: 4 x 100-150mg. ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Year of first operation | 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Contact details of the PT provider | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Provider | Contact person | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Phone: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Phone: 44 (0) 29218 32884 Fax: Email: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
If you find any mistakes please contact the responsible EPTIS coordinator in United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.